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Abstract
Background: Inflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in
which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible
associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in
patients through the acute phase of psychosis.
Methods: A total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge
or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for
the Assessment of Neuropsychological Status.
Results: There was an inverse relationship between overall cognitive performance and CRP level at admittance. The
association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses
statistically significant inverse associations were found between the CRP level and Delayed memory and Attention,
respectively. No associations were found between CRP level and other measures of psychopathology including
psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition
was no longer present. There was a significant increase in cognitive performance between baseline and follow-up.
There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels.
Conclusions: The findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive
dysfunctions in acute psychosis.
Trial registration: ClinicalTrials.gov ID; NCT00932529, registration date: 02.07.2009
Keywords: Schizophrenia, Cognition, Inflammation, CRP
Background
Schizophrenia and related psychoses are severe mental
disorders characterized by positive and negative psych-
otic symptoms, cognitive dysfunction and functional de-
cline, with a lifetime prevalence close to 1 % [1]. Positive
symptoms were until recently considered the most
prominent features of the disorders as reflected also in
the major diagnostic manuals, but cognitive dysfunctions
have for the last decade been recognized as core features
of schizophrenia [2–5], and with greater impact on func-
tional outcome than the psychotic symptoms [6–10].
The etiology of schizophrenia remains to be clarified,
but genetic as well as environmental factors convey risk
[11]. Involvement of inflammation and the immune sys-
tem in the pathophysiology of schizophrenia has re-
ceived particular attention in recent years, fueled also by
the genome wide association study (GWAS) findings of
associations between markers in the immune system in-
cluding the major histocompatibility complex and
schizophrenia risk [12–15]. Furthermore, preclinical-,
postmortem-, brain imaging-, and pharmacological stud-
ies, as well as clinical evidence from drug naïve first
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episode patients, strongly suggest a role for the immune
system in schizophrenia development (see for example
[16–18] for updated reviews). Emerging evidence indi-
cates that immuno-inflammatory processes may be par-
ticularly relevant to the cognitive dysfunctions of
schizophrenia [19–21].
The C-reactive protein (CRP), an acute-phase reactant
synthesized in the liver, has for many decades been con-
sidered a reliable marker of inflammation [22]. With
regards to cognition, a negative correlation has been
found between CRP levels and cognitive impairment in
the elderly, although not consistently [23, 24]. Scattered
reports also exist of inverse associations between CRP
levels and cognitive function in severe depression [25],
and in bipolar disorder [26]. In schizophrenia, a recent
meta-analysis by Fernandes et al. [27] consistently found
elevated serum levels of CRP in both first episode and
chronic phase patients, irrespective of medication status.
Furthermore, an association between CRP levels and
positive symptoms but not negative symptoms of psych-
osis was found. To the best of our knowledge, investiga-
tions of associations between the CRP level and
cognitive dysfunction in schizophrenia are however
scarce, although an association between CRP levels and
cognitive functioning in patients with predominantly
chronic schizophrenia has been reported in one cross-
sectional study [28]. Studies involving patient samples
representative of the acute and early phases of psychosis
are missing, as are studies with longitudinal measure-
ments. We have previously demonstrated a statistically
significant time effect for overall cognitive improvement
in acutely admitted psychosis patients during 24 months
of follow-up [29], but have not so far examined changes
in the acute phase.
The main aim of our study was accordingly to investi-
gate the association between the CRP level and cognitive
performance in a clinically representative sample of pa-
tients with psychosis acutely admitted to hospital, with
repeated measurements in the acute phase.
Methods
The materials and methods used have been described in
greater detail elsewhere [30]. The study is part of a prag-
matic, randomized trial comparing second generation
antipsychotics (SGAs) in the treatment of psychosis. The
present paper reports data obtained at baseline in pa-
tients who underwent cognitive assessments at admit-
tance and at discharge or after maximally 6 weeks if not
already discharged (termed as follow-up). This time
period corresponds to the acute phase of treatment.
Patients were consecutively recruited from March 2004
until February 2009 from the Haukeland University
Hospital with a catchment population of about 400,000.
The study was approved by the Regional Committee for
Medical Research Ethics, and by the Norwegian Social
Science Data Services. The study was publicly funded
and did not receive any financial or other support from
the pharmaceutical industry. The Regional Committee
for Medical Research Ethics allowed eligible patients to
be included before informed consent was provided, thus
entailing a clinically relevant representation in the study.
The patients were asked at follow-up for written in-
formed consent. All adult patients were eligible for the
study if they were acutely admitted to the emergency
ward for symptoms of active psychosis as determined by
a score of ≥4 on one or more on the items Delusions,
Hallucinatory behavior, Grandiosity, Suspiciousness/per-
secution, or Unusual thought content in the Positive and
Negative Syndrome Scale (PANSS) [31] and were candi-
dates for oral antipsychotic drug therapy. Accordingly
the patient inclusion encompassed the consecutive re-
cruitment of a clinically representative sample of psych-
osis patients acutely admitted to hospital. All eligible
patients met the ICD-10 diagnostic criteria (http://apps.
who.int/classifications/icd10/browse/2010/en) for schizo-
phrenia, schizoaffective disorder, acute and transient
psychotic disorder, delusional disorder, drug-induced
psychosis, bipolar disorder except manic psychosis, or
major depressive disorder with psychotic features. The
diagnoses were determined by the hospital’s psychiatrists
or specialists in clinical psychology. Patients were ex-
cluded from the study if they were unable to use oral an-
tipsychotics, were suffering from manic psychosis or for
other behavioural or mental reasons related to the state
of illness were unable to cooperate with assessments, did
not understand spoken Norwegian, were candidates for
electroconvulsive therapy, or were medicated with cloza-
pine on admittance. Patients with drug-induced psych-
oses were included only when the condition did not
resolve within a few days and when antipsychotic drug
therapy was indicated.
Clinical assessments
Before inclusion, eligible patients underwent the PANSS
structured clinical interview. Intra-class correlation coef-
ficients (ICC) were calculated based on inter-rater as-
sessments and showed high inter-rater reliability (0.92).
Furthermore, the Calgary Depression Scale for Schizo-
phrenia (CDSS) [32], and the Clinical Drug and Alcohol
Use Scales (CDUS/CAUS) [33] were used, and the pa-
tients were rated according to the Clinical Global
Impression—Severity of Illness scale (CGI-S) [34], and
the Global Assessment of Functioning—Split Version,
Functions scale (GAF-F) [35]. A blood sample was col-
lected from the patients between 08 and 10 a.m. for ana-
lyses of CRP levels. There was a change in the
laboratory’s CRP analysis methods in January 2005, and
hence only data obtained after this change is reported in
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the present work. The method used is the Tina-quant C-
reactive Protein (Latex) from Roche Modular P®, which
measures CRP levels >1 mg/L. Antipsychotic drug doses
were converted to defined daily doses (DDDs), in ac-
cordance with the World Health Organization Collabor-
ating Center for Drug Statistics Methodology (http://
www.whocc.no/atc_ddd_index/). The basic definition of
the DDD unit is the assumed average maintenance dose
per day for a drug used for its main indication in adults.
Cognitive assessment
Cognitive assessments were conducted at baseline and at
follow-up. A brief neuropsychological screening instru-
ment with alternative forms; the Repeatable Battery for
the Assessment of Neuropsychological Status (RBANS),
was used to minimize potential practice effects [36–38],
since longitudinal studies on cognitive functioning usu-
ally do not address the issue of practice effects suffi-
ciently [39, 40]. Practice effects can be particularly
evident when there are short time intervals between re-
peated neuropsychological testing, and the effect seems to
be strongest from baseline to the second testing [41, 42].
The RBANS has previously shown good reliability and val-
idity in psychosis [43]. It takes only about 30 min to
complete, making it practical and feasible to use in the
acute phases of psychosis. The five cognitive domains
were: Language; Visuospatial/ constructional; Immediate
memory; Delayed memory; and Attention. Raw scores
from the neuropsychological variables were converted to
t-scores by means of the norms from the manual [44]. The
final summary score based on the mean t-scores across
the five cognitive domains defined the overall cognitive
function t-score.
Statistical procedures
Categorical and continuous data at baseline were ana-
lyzed using exact χ2 – tests and one-way ANOVAs in
the SPSS software, version 20.0 (IBM SPSS Statistics,
2011). To investigate the association between cognitive
performance and CRP levels bivariate analyses of correl-
ation were conducted. This was followed by linear re-
gression analyses to adjust for potential confounders
between cognition and CRP. These confounders in-
cluded years of education, as a proxy for socioeconomic
status which may have an impact on both CRP levels
and cognitive performance [45]; medication status (i.e.
being antipsychotic drug naïve or previously exposed to
antipsychotic drugs) prior to inclusion, as antipsychotics
may influence both CRP levels and cognition [46, 47];
tobacco smoking, which has been associated with both
elevation of CRP levels [48, 49] and enhancement of
cognition [50, 51]; drug abuse, as a relationship between
drug abuse and CRP has been established [52, 53]; and
finally, cardiovascular risk, as CRP has been identified as
a risk factor for cardiovascular disease (CVD) [54, 55]
and CVD has been associated with cognitive impairment
[56, 57]. A CVD risk score was calculated based on the
International Diabetes Federation metabolic syndrome
definition cut-off values (http://www.idf.org/webdata/
docs/IDF_Meta_def_final.pdf ), by which each factor
(obesity, raised triglycerides, reduced HDL cholesterol,
raised blood pressure, and raised fasting plasma glucose)
was dichotomized as absent (0) or present (1), giving rise
to a maximal sum score of 5 for the individual factors.
Latent Growth Curve (LGC) models of level and
change in CRP and cognition were analyzed with the
Mplus program, version 7.20 [58]. Such models describe
both mean levels and individual variations in level and
change. In addition, the relation between level and
change is estimated. Because of only two measurement
points, baseline and follow-up, the residuals had to be
pre-specified in order to identify the model [59]. Mplus
allows unequal individual time-spaced observations to
be analyzed [60], and time was specified as weeks. The
default estimator for LGC modelling is maximum likeli-
hood with robust standard errors (MLR), which is robust
for non-normal data [60, 61]. Standard Mplus models
use all available data under the “missing at random”
assumption and minimize the effect of missing data
[62, 63]. First, unconditional separate LGC models
were analyzed, then a model integrating level and
change in both CRP and cognition was used in order
to study the relation between baseline levels in one
variable as a predictor of changes in the opposite
variable, after accounting for the control covariates.
Variables not accounting for any relations were re-
moved and model re-estimated based on a backward
hierarchical procedure [64].
The level of statistical significance was set at α = 0.05,
two-sided.
Results
A total of 124 patients were included with serum CRP
level measurements and cognitive assessments at base-
line. The demographic and clinical characteristics are
shown in Table 1. One patient used concomitant anti-
inflammatory medication (prednisolone). None of the in-
cluded patients were diagnosed with inflammatory- or
immunological disorders or infections during the study.
Baseline
The mean CRP level with standard deviation (SD) at ad-
mission was 3.6 (5.2) mg/L and the mean overall cogni-
tive function t-score was 37.8 (7.7).
The cognitive subdomain t-scores were 40.5 (7.8); 45.8
(12.7); 35.7 (10.2); 37.6 (12.1); and 29.5 (8.9) for Lan-
guage; Visuospatial/ constructional abilities, Immediate
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memory; Delayed memory; and Attention, respectively
(Fig. 1).
In the primary analyses, the Pearson correlation test
revealed a statistically significant inverse relationship
between overall cognitive performance and CRP level
at baseline (Pearson correlation r = −0.247, R2 = 0.061,
p = 0.006) (Fig. 2). In a linear regression model with
overall cognitive performance as the dependent variable
and CRP, years of education, antipsychotic drug status
before inclusion, tobacco smoking status, drug abuse,
and CVD risk score as independent variables, the asso-
ciation remained statistically significant between cogni-
tive performance and CRP (B = −0.290; Beta = −0.198;
p = 0.031). No interaction effects were found between
CRP and any of the other independent variables that
significantly improved the model. In the secondary analyses
there were statistically significant inverse associations
between CRP level and Delayed memory (B = −0.484;
Beta = −0.213; p = 0.02) and Attention (B = −0.404;
Beta = −0.239; p = 0.012), whereas no association was
found between CRP and Language, Visuospatial/con-
structional abilities, or Immediate memory, respect-
ively. In a sensitivity analysis that included also the
PANSS positive symptoms scale score, the results
remained unchanged.
In Pearson correlation tests of the relationships be-
tween CRP and the PANSS total score, the scores of the
PANSS positive, negative, and general psychopathology
subscales, the CDSS, the GAF-F, and the CGI, respect-
ively, no statistically significant correlations were found
(r < 0.100 for all).
Based on visual inspection of the CRP levels versus over-
all cognitive performance scatterplot, the bulk of data were
in the lower end of the CRP levels (Fig. 2). Accordingly
sub-analyses were conducted that included only patients
with CRP levels <15 mg/ L (N = 119). The inverse associ-
ation between CRP levels and overall cognitive performance
was strengthened (B = −0.741; Beta = −0.300, p = 0.001). In
the cognitive subdomains statistically significant associa-
tions with CRP levels were found for all domains except
Immediate memory. When only the schizophrenia sub-
group (N = 36) was included, the inverse association be-
tween CRP levels and overall cognitive performance was
markedly increased ((B = −1.031; Beta = -0.529; p = 0.006).
In sensitivity analyses that included only the sub-
group of drug naïve patients (N = 64), the inverse relation-
ship between CRP level and overall cognitive performance
remained essentially unchanged compared to in the pri-
mary analyses with the full sample, although the correl-
ation was no longer statistically significant (B = −0.568;
Beta = −0.194; p = 0.187).
In sensitivity analyses excluding the patient using
prednisolone the results were unchanged.
Follow-up
A total of 62 patients were retested using the RBANS B
at follow-up. The mean interval between baseline and
follow-up was 28.3 (11.1) days. The mean PANSS total
and CGI-S scores were 53.9 (13.9) and 3.6 (1.0),
Table 1 Baseline demographics and clinical characteristics
(N = 124)
Characteristics
Gender N % of sample
Male 84 67.7
Female 40 32.3
Antipsychotic drug naïve 64 51.6
Alcohol use last 6 months
None 17 13.7
Misuse 15 12.1
Illicit drug use last 6 months
None 82 66.1
Use/ Misuse 25 20.2
Current tobacco smoking 64 51.6
Diagnosisa







Body Mass Index 23.5 4.6/ 15.8–40.3
Years of Education 12.5 2.7/ 8–22
PANSS Total 73.4 11.9/ 45–98
PANSS Positive 20.1 4.1/ 12–30
PANSS Negative 19.0 6.9/ 7–38
PANSS General 34.3 6.4/ 20–56
CDSS 6.2 5.0/ 0–23
GAF-F 30.5 4.9/ 18–45
CGI 5.2 0.6/ 4–6
RBANS t-score 37.8 7.7/ 20.2–58.8
N number of patients, SD standard deviation; Antipsychotic drug naive = No
life-time exposure to antipsychotic drugs before index admission; Misuse =
Misuse or Dependence according to the Clinical Drug and Alcohol Use Scales
(CDUS/CAUS), patients with no illicit drug use could be included in the category
alcohol use last 6 months; Schz and related = Schizophrenia and related disorders:
Schizophrenia, schizo-affective disorder, acute polymorphic psychotic disorder
with symptoms of schizophrenia, acute schizophrenia-like psychotic disorder,
delusional disorder; Acute = Acute psychosis other than those categorized under
Schz and related; Affective = Affective psychosis; Rest =Miscellaneous
psychotic disorders. All diagnoses are according to ICD-10; PANSS the Positive and
Negative Syndrome Scale, CDSS the Calgary Depression Scale for Schizophrenia,
GAF-F the Global Assessment of Functioning, split version, Functions scale, CGI the
Clinical Global Impression, severity of illness scale, RBANS the Repeatable Battery for
the Assessment of Neuropsychological Status
aPatients with missing diagnoses are not included in the list
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respectively, corresponding to being mildly ill. There
were no statistically significant differences between those
tested only at baseline and those with follow-up tests for
any of the clinical or demographic characteristics at
baseline presented in Table 1. Medication details are dis-
played in Table 2.
The distribution of CRP levels and overall cognitive per-
formance is displayed in Fig. 3. The mean CRP level and
overall cognitive performance were 4.6 (10.6) mg/L and
41.3 (7.1), respectively. The association between CRP level
and overall cognitive performance was not statistically sig-
nificant at follow-up (B = −0.045; Beta = −0.066;
p = 0.627). In sensitivity analyses that included also dur-
ation of treatment between baseline and follow-up, as well
as the mean defined daily dose of antipsychotics for the
latter 7 days before follow-up, the results remained un-
changed. In sensitivity analyses excluding the single pa-



























Fig. 1 Cognitive performance by functional domain. Notes: ♦ =mean t-score with bars representing plus/minus 1 standard deviation from
the mean
Fig. 2 Association between CRP level and overall cognitive performance at baseline. Notes: Scatter plot of overall cognitive performance versus
CRP level (N = 124). Pearson correlation r = −0.247, r2 = 0.061, p = 0.006. In sensitivity analyses excluding outliers with CRP >15 (N = 119): Pearson
correlation r = −0.346, r2 = 0.120, p = 0.000
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The results from the LGC models are presented in
Table 3 with mean and individual variation in baseline
level and change, and the relation between baseline level
and change. There was no statistically significant mean
increase in CRP, but considerable and statistically signifi-
cant individual variation in the change (Table 3). The re-
lation between baseline level and change was not
statistically significant.
Regarding cognition, there was a statistically signifi-
cant mean increase over time, however; with some
patients changing more than others indicated by statisti-
cally significant variance. For this variable it was found a
negative relationship between baseline score and degree
of change, which indicates stronger rate of change for
patients with lower baseline scores. Figure 4 illustrates
this with mean change over a four week period and
changes for patients with lower (−1 SD) and higher (+1 SD)
baseline scores.
The results from the final model consisting of two
growth processes with level and change in CRP and
overall cognition showed that baseline level in CRP could
predict changes in overall cognition (b = 0.04, p = 0.000),
after accounting for the covariate variables. Changes in
overall cognition were not related to changes in CRP
(b = −0.02, p = 0.764). The covariate variables showed
smokers to have less increase over time than non-
smokers (b = −0.18, p = 0.001) and that baseline CRP
level was moderated by the CVD risk baseline level
(interaction term: b = −0.06, p = 0.041). The main effect
of CVD risk was not found to be statistically significant
(b = 0.34, p = 0.072). This finding indicates a stronger
increase in overall cognition scores in patients with
higher baseline CRP levels, however, with stronger in-
creases in patients with lower degree of CVD risk
scores, and in non-smokers.
Discussion
The main finding of the present study was an inverse re-
lationship at baseline between serum levels of CRP and
overall cognitive performance, as well as for the
Table 2 Antipsychotic drug use at discharge/ 6 weeks
Risperidone Olanzapine Quetiapine Ziprasidone Aripiprazole
N = 14 N = 21 N = 14 N = 10 N = 1
Mean (SD/ range) Mean (SD/ range) Mean (SD/ range) Mean (SD/ range) Mean (SD/ range)
Mean dose (mg/ d) 3.3 (1.2/2.0–6.0) 16.6 (4.7/10.0–25.0) 480.4 (218.9/175.0–800.0) 82.0 (38.2/20.0–160.0) 5.0 (-)
Serum level (nm/ L)a 58.5 (33.3/ 27.0–147.0) 115.5 (70.3/47.0–302.0) 546.8 (585.3/ 62.0–1817.0) 88.6 (89.3/ 13.0–323.0) 141 (-)
N number of patients, SD standard deviation, mg/d milligrams per day, nm/L nanomoles per litre. There was missing medication data on 1 patient and 1 patient
had discontinued the antipsychotic medication
aReference ranges: Risperidone 30–120; Olanzapine 30–200; Quetiapine 100–800; Ziprasidone 30–200; Aripiprazole 200–1300
Fig. 3 Association between CRP level and overall cognitive performance at follow-up. Notes: Scatter plot of overall cognitive performance versus
CRP level (N = 62). Pearson correlation r = 0.007, r2 = 0.000, p = 0.958. In sensitivity analyses excluding outliers with CRP >15 (N = 60): Pearson correlation
r = 0.005, r2 = 0.000, p = 0.972
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subdomains Delayed memory and Attention, in a clinic-
ally relevant sample tested in the acute phase of psych-
osis. The association was particularly strong for the
subgroup with a diagnosis of schizophrenia. At follow-
up, which in time correspond to the end of the acute
phase, the association was no longer present. The find-
ing was restricted to cognitive performance, as none of
the other psychometric parameters tested were associ-
ated with the CRP level. The CRP level at baseline pre-
dicted the overall cognitive change.
Our results are consistent with those of Dickerson et
al. [28], who reported an inverse relationship between
CRP levels and cognitive performance but no association
towards other measures of psychopathology. Our study
adds new knowledge by including a consecutive sample
of patients acutely admitted for psychosis, with measure-
ments both at hospital admission and at discharge or
after maximally 6 weeks, thus giving the possibility to
analyze the data also with regard to longitudinal
changes. We argue that this period of time reflects the
phase of treatment with the most severe symptoms, sup-
ported by the decrease of the CGI-S scores from mark-
edly ill at baseline to mildly affected at follow-up.
Interestingly, the negative association between CRP
levels and overall cognitive performance was present
only at baseline. Since the sample at follow-up was
smaller than at baseline, the lack of statistically signifi-
cant difference at follow-up could be due to insufficient
statistical power. However, the correlation was reduced
substantially at follow-up, approaching zero, which
makes the lack of association unlikely to be a sample
size problem. Another possibility might be that the attri-
tion was not at random, giving rise to selection bias at
follow-up compared to the sample at baseline. This
seems unlikely, however, as attrition was not related to
any baseline characteristics. Finally, cognitive dysfunc-
tion might theoretically be associated with positive
symptoms of psychosis, and the positive symptoms
could accordingly confound the association between
CRP and cognitive performance, which could also ex-
plain why the association between CRP and cognitive
performance disappeared in remission. A sensitivity ana-
lysis was therefore undertaken to adjust for the potential
contribution from positive symptoms, but the results
remained unchanged, which is also in line with the find-
ing of a meta-analysis on the subject [65]. Taken
Table 3 Level and change results for CRP level and overall cognition based on latent growth curve models
Baseline (I) Change (S) Relation I,S
Mean Variance Mean Variance Cov r
CRP level 2.76*** 9.70 0.98 26.52 −1.33 −.08
Overall cognition 37.92*** 60.83 0.95*** 3.66 −5.53 −.37**
The model describes mean level and individual variations in baseline and change over time. The relation between intercept (I) and slope (S) describes the relation
between baseline level and rate of change (covariances and correlations). Cov covariance, r correlation coefficient























Fig. 4 Model estimated cognitive change during follow-up. Notes: The figure shows mean change and change based on ± 1 SD baseline level.
Patients with lower cognitive scores had a higher rate of change. SD = standard deviation
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together, the inverse association between CRP and cog-
nition may accordingly be interpreted as at least partly
state dependent.
In our study, there was no association between CRP or
any of the clinical variables, which is not entirely in line
with the findings in the meta-analysis by Fernandes et al.
[27], who found an association between CRP and posi-
tive but not negative symptoms. The meta-analysis was
based on about 2,000 schizophrenia subjects and healthy
controls, and the apparent lack of an association in our
much smaller sample may be related to insufficient stat-
istical power. Our results are, however, in correspond-
ence with the Dickerson et al. [28] study finding no
association between CRP and any psychiatric symptoms.
The mean overall cognitive t-score increased significantly
between baseline and follow-up, and although the mean
CRP levels were almost identical at the assessment points,
the distribution changed substantially towards the cognitive
t-scores. Furthermore, the baseline CRP level was found to
predict change of cognitive performance. Hypotheses
regarding the biological substrate mediating the
inflammation-related effects on cognition can only be
speculative. There is however phase-specific fluctuations re-
ported for both myelin integrity and glutamate levels in
schizophrenia [66–70]. Considerable cross-talk has been
suggested between immuno-inflammatory processes, mye-
lin, and glutamate in schizophrenia, as recently reviewed by
Kroken et al. [21]. CRP is known to activate complement,
and the complement system have demonstrated different
and somewhat paradoxical effects in the central nervous
system (CNS) [71–73]. Some of these effects could be rele-
vant to neurodegeneration and inflammation in several
brain disorders including Alzheimer’s disease [72]. Inflam-
matory processes may also decrease the blood–brain-bar-
rier integrity, leaving the CNS more vulnerable to
complement protein infiltration from the periphery [74].
The present study also supplements the findings of
Dickerson et al. [28], as more than half the sample was
antipsychotic drug naïve, which could be used as a proxy
for early stage psychosis. The sub-analyses in the drug-
naïve patients revealed similar findings to those of the
total sample, with almost identical B and Beta values.
The non-significant p-value is probably related to insuf-
ficient statistical power in the small sample of drug naïve
patients. This interpretation is further supported by the
fact that entering medication status into the regression
did not change the association between CRP and cogni-
tion, which might indicate that the association between
CRP levels and cognition was not a result of longstand-
ing psychosis or medication (adverse) effects.
The cognitive deficits in schizophrenia are generally
considered to be stable over time [75, 76]. At odds with
this, we have previously reported an overall cognitive
performance improvement across time that was
considered clinically significant, and with some differen-
tial cognitive effectiveness among different second gen-
eration antipsychotics when data from the whole follow-
up period was analyzed [29]. In the present study, all but
one patient used antipsychotics at follow-up. It cannot
be ruled out that the significant cognitive improvement
observed also in the acute phase is antipsychotic drug-
related, but due to the lack of a placebo group no firm
conclusions can be drawn. It should be noted that anti-
inflammatory effects of antipsychotic drugs have been
reported in several studies [77, 78], providing a putative
link to any cognitive enhancement mediated by the
drugs in the present study.
We found significant inverse associations between
CRP levels and Delayed memory, and Attention subdo-
mains, respectively, whereas no significant associations
were present for the other subdomains. Aas et al. [79]
found overall cognitive impairment present already in
first episode psychosis patients with the largest effect
sizes for verbal memory, executive function, and general
IQ. Correspondingly, a global impairment was found
across all the subdomains in our sample, the Attention
subdomain had the lowest t-score, followed closely by
the Immediate memory and Delayed memory subdo-
mains. Seeking reasons for the associations with CRP
levels being present only in some of the subdomains is
outside the scope of this study. It is nevertheless an in-
teresting observation that the inverse association is
present in the subdomains showing the most pro-
nounced impairments which might indicate a greater
vulnerability to inflammation-related processes com-
pared to other subdomains of cognition.
Some limitations to the study should be mentioned.
Minor elevations in the CRP levels are associated with
numerous conditions and although we adjusted for sev-
eral potential confounders we may have missed other
unknown or hidden confounders between CRP levels
and cognitive performance. However, most of the condi-
tions associated with minimal CRP elevations do not
have an apparent relationship towards cognitive func-
tion, making them less likely to confound the results
presented here. As already discussed, the attrition rate
was substantial, and selection bias cannot be ruled out,
although attrition was not related to any baseline char-
acteristics. We used only CRP as a measure of inflamma-
tion, and clearly a broader display of inflammatory
markers would have added further strength to the study.
Finally, although the association found for the primary
outcome was highly statistically significant, the explained
variance was only modest.
Conclusions
Despite the limitations mentioned, the data support an
inflammatory component to the cognitive impairment in
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schizophrenia and related psychoses, which may be at
least partly state dependent. Several anti-inflammatory
agents have shown promising results as add-ons to anti-
psychotic drug treatment in schizophrenia [80, 81]. Future
studies should prospectively and repeatedly examine lon-
gitudinal changes in CRP and other markers of inflamma-
tion, and their association with cognitive performance. If
our results are replicated, anti-inflammatory drugs may be
especially beneficial in the acute phase of psychosis for
cognitive enhancement.
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